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Abstract
Background: The discovery that heterozygous missense mutations in the gene encoding triggering receptor
expressed on myeloid cells 2 (TREM2) are risk factors for Alzheimer’s disease (AD), with only the apolipoprotein E
(APOE) ε4 gene allele conferring a higher risk, has led to increased interest in immune biology in the brain. TREM2
is expressed on microglia, the resident immune cells of the brain and has been linked to phagocytotic clearance of
amyloid β (Aβ) plaques. Soluble TREM2 (sTREM2) has previously been measured in cerebrospinal fluid (CSF) by
ELISA but in our hands commercial kits have proved unreliable, suggesting that other methods may be required.
We developed a mass spectrometry method using selected reaction monitoring for the presence of a TREM2
peptide, which can be used to quantify levels of sTREM2 in CSF.
Findings: We examined CSF samples from memory clinics in Sweden and the UK. For all samples the following
were available: clinical diagnosis, age, sex, and measurements of the CSF AD biomarkers Aβ42, T-tau and P-tau181.
AD patients (n = 37) all met biomarker (IWG2) criteria for AD. Control individuals (n = 22) were cognitively normal
without evidence for AD in CSF. We found significantly higher sTREM2 concentration in AD compared to control
CSF. There were significant correlations between CSF sTREM2 and T-tau as well as P-tau181. CSF sTREM2 increase in
AD was replicated in a second, independent cohort consisting of 24 AD patients and 16 healthy volunteers.
Conclusion: CSF concentrations of sTREM2 are higher in AD than in controls, and correlate with markers of
neurodegeneration. CSF sTREM2 may be used to quantify glial activation in AD.
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Introduction
Homozygous mutations in the triggering receptor
expressed on myeloid cells 2 (TREM2) are known to cause
polycystic lipomembranous osteodysplasia with sclerosing
leukoencephalopathy, also known as Nasu-Hakola disease
(NHD) [1, 2]. The disease is initially characterised by ankle
swellings and frequent bone fractures, however as the
disease progresses a neurological syndrome develops that
resembles the behavioural variant of frontotemporal de-
mentia (bFTD) [3]. Recently, dementia-like symptoms
without bone involvement have been reported in patients
with homozygous missense mutations in the TREM2 gene
[4]. Further to this, heterozygous mutations in the TREM2
gene have been identified as risk factors for Alzheimer’s
disease (AD), Parkinson’s disease (PD), amyotrophic lat-
eral sclerosis (ALS) and FTD [5–9], although a recent
study utilizing detailed clinical phenotyping and TREM2
sequencing found that the most disease-associated muta-
tion (R47H) is a risk factor only for AD and not other
neurodegenerative diseases [10]. However, these findings
still suggest a crucial role for TREM2 in maintaining
homeostasis and modulating inflammation in the brain.
TREM2 is a receptor glycoprotein of 230 amino acids
which belongs to the immunoglobulin superfamily. In the
brain, TREM2 is expressed exclusively by myeloid cells
which include microglia, the brain’s resident immune cells
[11]. In vitro, TREM2 promotes phagocytosis, suppresses
toll like receptor-induced inflammatory cytokine produc-
tion and enhances anti-inflammatory cytokine transcrip-
tion [12, 13].
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Given the role TREM2 plays in immune function and
the increased risk of disease that variants cause, we set
out to investigate TREM2 levels in the CSF of well char-
acterised AD cases and compare them to controls using
a novel selected reaction monitoring (SRM) technique.
Methods
Subjects
The study included 37 AD patients who fulfilled the
revised proposed International Working Group (IWG2)
criteria [14] in which, for research purposes, a clinical
diagnosis of AD should be supported by a typical AD
biomarker profile of concomitant tau and Aβ pathology.
Neurodegeneration and neurofibrillary tangle pathology
are reflected in the CSF by increased total tau (T-tau)
and phospho-tau (P-tau) concentrations, respectively
[15–18] whereas cerebral Aβ plaque pathology is
reflected by reduced CSF levels of the 42 amino acid-
long, aggregation-prone Aβ protein (Aβ42) [19, 20]. To
determine AD pathology, we used the cut-offs for CSF
T-tau, P-tau and Aβ42 established by Duits et al., i.e., a
CSF total tau/Αβ42 ratio of more than 0.52, and an
Aβ42 concentration of less than 550 pg/ml [21]. Further,
22 control individuals who were cognitively normal and
had a negative CSF AD biomarker profile were included.
Controls from Sweden were all cognitively normal vol-
unteers (n = 16). The remaining controls from the UK
cohort were patients who sought treatment for non-
neurodegenerative disorders including depression. One
of the AD patients was considered an outlier due to exces-
sively high T-tau and P-tau measurements (T-tau
5894 pg/ml, P-tau 363 pg/ml) and was removed from the
analysis. This did not affect the results. In the same round
of experiments as for the original AD-control analyses, 6
patients with other neurodegenerative diseases were ana-
lysed (2 patients with FTD, 2 patients with semantic
dementia, 1 patient with corticobasal syndrome (CBS) and
1 patient with dementia with Lewy bodies (DLB). These
were diagnosed according to standard clinical criteria as
previously described [22, 23]. Twenty-four AD patients
and 16 healthy volunteers, diagnosed according to the
same criteria as for the discovery cohort, were used to test
for replication of the findings. Neither patients nor
controls were on cortisol treatment, but there was no
information on the potential use of non-steroidal anti-
inflammatory drugs.
The study was approved by the regional ethics com-
mittees at UCL and the University of Gothenburg.
Experimental protocols
CSF was collected prospectively in polypropylene tubes
according to standard operating procedures, in the morn-
ing, at the two sites, then aliquoted into polypropylene
tubes and frozen within 2 hours of being collected. After
being stored at -80 °C CSF was thawed, then 100ul was
pipetted off, freeze dried, and subjected to in-solution
digestion. Twenty μl of digest buffer was added (100 mM
Tris, pH 7.8 containing 6 M urea, 2 M thiourea and 2 %
amidosulfobetaine-14) plus yeast enolase as an internal
standard. Protein disulphide bridges were reduced by the
addition of 1.5 μL of 100 mM Tris-HCl pH 7.8 containing
5 M dithiothreitol and free thiol groups were carboamido-
methylated by incubation with 3 μL of 100 mM Tris-HCl
pH 7.8 containing 5 M iodoacetamide. The solution was
diluted to a final volume of 200 μl, vortexed and 1 μg of
sequence grade trypsin was added. Samples were then
incubated for 12-16 hr in a water bath at 37 °C.
In order to design a single reaction monitoring (SRM)
assay for TREM2, a unique 13 amino acid-long TREM2
peptide was synthesized. This peptide was chosen so that
it was not subject to post-translational modifications such
as phosphorylation or glycosylation and not affected by
known genetic polymorphisms or mutations (Fig. 1a). The
assay was established on a Waters Acquity UPLC coupled
to a Xevo TQ-S triple quadrupole mass spectrometer, as
previously described [24]. The instrument was operated in
positive ion mode. The capillary voltage was maintained at
3.7 kV, with source temperature held constant at 150 °C
and nitrogen used as the nebulising gas at a flow rate of
30 L/h. For the TREM2 peptide, precursor ion masses
were determined in scan mode with product ion masses
determined following collision-induced dissociation with
argon. Two transitions were selected for confirmatory
purposes; clean transitions without interfering peaks were
used. Custom synthesised peptides (Genscript, USA) were
used to optimise the peptide detection and to determine
the retention time and identify unequivocally the correct
peaks/s in CSF. A single 10ul volume of each CSF digest
was injected onto a Waters CORTECS UPLC C18 + Col-
umn, 90 Å, 3 mm × 100 mm column attached to a C18+
VanGuard pre-column. UPLC and MS tune conditions
were performed as described previously [25]. Dynamic
Multiple Reaction Monitoring was performed over a
10 minute gradient with a minimum of 0.01 sec dwell time
for quantitative transitions and a minimum of 12 data
points per peak on Waters Xevo TQ-S MS.
QC runs of pooled CSF digests were run in triplicate at
the start of the run and then every 10 injections. A CV
within 10 % for each QC was considered acceptable. CSF
was spiked with sTREM2 peptides to create a calibration
curve with average concentrations of biomarker levels and
analysed for intra- and inter-batch variations that were
below 10 %. The curve was linear up to 40 pmols.
CSF T-tau, P-tau and Aβ42 were analysed using
INNOTEST enzyme-linked immunosorbent assays (ELI-
SAs) (Fujirebio Europe N.V., Gent, Belgium). Plasma C-
reactive protein (CRP) was measured using a commercial
immunoturbidimetry assay on a Cobas 6000 instrument
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according to the manufacturer’s instructions (Roche Diag-
nostics, Penzberg, Germany). CSF YKL-40 and CCL2 were
measured with commercially available enzyme-linked im-
munosorbent assays (R&D Systems, Minneapolis, Minne-
sota, USA) according to the manufacturer’s instructions.
Data and statistical analysis
Mass spectrometry data were analysed using Mass Lynx
version 4.1 and GraphPad Prism. D’Agostino-Pearson test
for normality was performed on all data. As most of the
parameters displayed skewed distributions, non-parametric
tests were used for all comparisons (Mann Whitney U) and
correlations (Spearman’s rank). Gender differences were
assessed by χ2 test. Threshold for significance was set
at p < 0.05.
Results
There were no significant differences in gender, age or
plasma CRP breakdown between AD and control groups
(Table 1). Despite there being a trend towards higher
plasma CRP levels in controls, there was no correlation
between plasma CRP levels and CSF sTREM2 levels in
AD patients or controls (r = -0.004833 p = 0.9764).
As expected, the AD subjects had significantly lower
MMSE scores and Aβ42 levels, and significantly higher
concentrations of T-tau, P-tau and T-tau/Aβ42 ratios
compared with controls (Table 1). CSF sTREM2 concen-
trations were significantly higher in AD patients compared
with controls (Table 1, Fig. 1b, p = 0.0457). Analysing the
AD and control samples separately, P-tau was positively
correlated with sTREM2 in the AD subjects (p = 0.0002)
but not in controls. There were no significant correlations
between sTREM2 and either T-tau or Aβ42; there was also
no correlation between MMSE score and sTREM2 levels in
either AD patients or controls. However, when analyz-
ing AD and control individuals together, there was a
positive correlation of sTREM2 levels with both T-tau
(Fig. 1c, r = 0.3863 p = 0.0023) P-tau (Fig. 1d, r = 0.5331
p = < 0.0001) but not with Aβ42 (Fig. 1e). Cardiovascular
risk factors such as stroke, hypertension and smoking were
not associated with CSF sTREM2 concentration (p > 0.05
for all comparisons). In a subset (52 subjects), CSF sTREM2
correlated positively with YKL-40 (r =0.3271, p = 0.0204,
Fig. 1f) and a similar trend was seen for CSF CCL2,
although not significant (r = 0.28, p = 0.07). CSF sTREM2
concentrations were similar in APOE ε4-positive and APOE
ε4-negative AD patients (p = 0.5917), as well as in
APOE ε4-positive and APOE ε4-negative control indi-
viduals (p = 0.2735). In the same round of analyses, CSF
sTREM2 was measured in 6 patients with other neuro-
degenerative diseases (2 patients with FTD, 2 patients
with semantic dementia, 1 patient with CBS and 1 pa-
tient with DLB). The one CBS case was the only patient
with a sTREM2 concentration above 200 pg/mL. The other
patients all had control-like concentrations (Additional file
1: Table S1). We replicated the results in an independent
(See figure on previous page.)
Fig. 1 Increased CSF sTREM2 concentration in AD. a shows a cartoon of the TREM2 peptide indicating in red the peptide sequence and location.
b SRM-based analysis of sTREM2 levels in AD cases and controls shows sTREM2 present in all samples (n= 59) but a significant increase (p = 0.0457)
is observed in AD cases (n = 37). c There is a significant correlation between CSF T-tau and sTREM2 (r = 0.3863 p = 0.0023). This is also seen (d) when
comparing P-tau and sTREM2 (r = 0.5331 p = < 0.0001). However, there is no significant correlation between sTREM2 levels and Aβ42 (r = -0.2097
p = 0.1280) (e). Levels of YKL-40 correlate positively with sTREM2 levels (f) (r = 0.3271 p = 0.0204). g In a second cohort we replicate the finding that
CSF sTREM2 levels are increased in AD cases (p = 0.0312)
Table 1 Characteristics of AD patients and controls
Subject details Controls (n = 22) AD patients (n = 37) p value
Gender (F/M), no (%) 10(45)/12(55) 19(53)/18(47) 0.6
Age, years (mean ± SD) 69.2 ± 8.0 70.51 ± 7.5 0.54
MMSE score (median IQR) 29.00(26.50-29.00) 22.00(18.00-25.00 <0.0001
APOE ε4 positive (%) 33 % 67 % 0.0002
Plasma CRP (mg/L), median (IQR) 2.095 (0.8425 – 4.7535) n = 16 1.020 (0.6500 – 1.295) n = 25 0.0543
CSF Biomarkers
Aβ1-42 (pg/ml), median (IQR) 978.5(821.8-1045) 367.0(301.0-433.0) <0.0001
T-tau (pg/ml), median (IQR) 239.5(196.3-279.0) 596.0(455.0-858.5) <0.0001
P-tau181 (pg/ml), median (IQR) 45.0(36.8-58.3) 95.0(75.0-111.5) <0.0001
T-tau/Aβ1-42 ratio, median (IQR) 0.25(0.19-0.33) 1.56(1.24-2.55) <0.0001
sTREM2 (pg/ml), median (IQR) 195.6(131.0-240.7) 231.2(172.5-305.4) 0.0457
Data expressed as mean ± SD or median (IQR) as appropriate. Probability values (p) denote differences between control and AD. A χ2 test was used for gender
and APOE genotype comparisons. CSF biomarkers and sTREM2 were evaluated using the Mann-Whitney U test
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study of 24 patients with AD and 16 healthy controls, again
showing elevated CSF sTREM2 in AD (Fig. 1 g, p = 0.0312
and Additional file 2: Table S2).
Discussion
Since the publication of papers attributing a higher risk of
AD in those carrying variants in the TREM2 gene [5, 26],
an enormous amount of work has focused on this gene
and its protein product. TREM2 variants have also been
implicated in the risk for other neurodegenerative diseases
such as PD [6, 7], FTD [7, 8] and ALS [9]. These findings
implicate TREM2 in the pathogenesis of AD and likely
other neurodegenerative diseases. Here, we show that CSF
concentrations of sTREM2 are increased in AD and
correlate with markers of neurodegeneration and glial
activation, but not amyloid deposition.
In their recent paper, Kleinberger et al. [27] used an in-
house ELISA to measure levels of sTREM2 in patients
with AD and FTD, as well as in patients with homozygous
TREM2 mutations that cause or are predicted to cause
loss of function of TREM2 (p.T66M and p.Q33X). Whilst
it was impossible to measure sTREM2 in the CSF or
serum of the homozygous mutation patients, they did find
reduction in CSF sTREM2 in the AD patients [27]. We
found these results surprising for a number of reasons.
First, TREM2 variants associated with AD and reduced
TREM2 secretion are rare and should not influence CSF
levels in a downward manner in sporadic AD. Second, a
study on a number of different mouse models of AD,
which measured mRNA expression in different parts of
the brain, showed expression of the Trem2 gene to be
increased in cortex, cerebellum, and hippocampus in all
models by 18 months of age [28]. Finally, as inflammation
has been linked to AD in many studies (for review see
[29]), one would expect that CSF markers of neuroin-
flammation – and so perhaps CSF sTREM2 concentra-
tion – would be increased rather than decreased in AD.
This is supported by the finding that CSF concentra-
tions of sTREM2 in patients with multiple sclerosis
(MS) and other inflammatory diseases were found to be
higher than concentrations measured in CSF from non-
inflammatory neurologic disease patients [30], corrob-
orating that the marker reflects neuroinflammatory
processes in the CNS. Prior to using the method we
developed for this study, we attempted to use a com-
mercial ELISA to measure sTREM2 but were unable to
validate it.
To explore the relationship between CSF sTREM2 and
AD in more detail, we aimed to combine detailed phe-
notyping of patients and controls with highly accurate
measurement of sTREM2. For the former we included
conventional CSF biomarkers to ensure as far as possible
that individuals with AD had AD pathology; and con-
versely to ensure a pure control group who did not have
evidence of asymptomatic AD pathology. For the latter,
we used a very sensitive recently developed SRM assay
[24] and adapted it to measure sTREM2. Using these
methods, we found a significant increase in sTREM2
concentrations in the CSF of AD subjects and, additionally,
we showed that sTREM2 concentrations correlated posi-
tively with T-tau and P-tau concentrations in the whole
data set, whereas no such correlation was seen for CSF
Aβ42. Whilst the correlation was lost for T-tau when con-
sidering AD patients separately, the correlation between
sTREM2 and P-tau remained. Further, we showed that
sTREM2 does not seem to depend on APOE genotype, as
there was no difference in CSF sTREM2 concentrations
between APOE ε4 carriers and non-carriers. Finally, a posi-
tive correlation of CSF sTREM2 with the astroglial marker
CSF YKL-40 [31, 32] and a trend for a similar correlation
with CSF CCL2, a putative microglial marker [33], support
that CSF sTREM2 may reflect glial activation. It may be
argued that YKL-40 is expressed in both astrocytes and
microglia [31, 32] and that it therefore is hard to dissect the
individual contribution of astrocytes and microglia to CSF
sTREM2 elevation. However, so far TREM2 expression has
only been observed in microglia and not in astrocytes or
other cell types of the brain [34, 35]. We therefore find it
likely that most CSF sTREM2 represents release from
microglia, although we cannot rule out interplay between
activated astrocytes and microglia in the release mechan-
ism. In regards to disease specificity, our data prevent us
from making a conclusive statement, but it is interesting to
note that among the 6 cases with neurodegenerative dis-
eases other than AD, only the one CBS patient (a condition
that often displays AD pathology) had a high CSF sTREM2
concentration, whereas the other 5 cases had CSF sTREM2
concentrations in the lower control range. Cases for these
other neurodegenerative diseases will be collected so a
properly powered study can be conducted in the future.
There are many potential roles for inflammation in the
pathogenesis of AD with one possibility being that Aβ
deposition occurs independent of inflammatory processes,
but that the type and extent of inflammatory response to
Aβ deposition within the brain might trigger or influence
subsequent neurodegeneration [36]. Our data provide
support for this hypothesis: the absence of correlation of
CSF sTREM2 and Aβ42 suggests that increased sTREM2
release from microglia is not primarily related to Aβ
deposition; whilst the relationship between CSF sTREM2
and tau proteins in particular suggests that an increased
inflammatory response is related to neurodegeneration.
The mechanism for the release of sTREM2, and also T-
tau and P-tau, to the CSF is not known in detail. CSF T-
tau concentrations probably reflect the intensity of neur-
onal damage and degeneration, with higher levels correlat-
ing with amount of damaged tissue, rate of progression
and mortality [37], i.e. higher amounts of tau are released
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to CSF with more intense neurodegeneration. For CSF
P-tau, the situation is more unclear, since some studies
report correlations between high P-tau levels and cor-
tical tangle pathology, while others studies, similar to
T-tau, report correlations between high CSF P-tau and
higher rate of progression and cognitive decline [37].
These preliminary results do not suggest a mechan-
ism for sTREM2 in the pathogenesis of AD, but do
indicate that further studies are required to unravel
the role that this protein plays in neuroinflammation
and neurodegeneration.
Conclusions
The results of our pilot study suggest that CSF sTREM2 is
higher in AD subjects and may be a novel marker of glial
activation in AD primarily related to neurodegenerative
aspects of the disease and not Aβ pathology. The overlap
between cases and controls, however, suggests that the
diagnostic usefulness may be limited. Nevertheless, if
replicated in larger studies, this may provide important
insights into the pathogenic process in AD, and provide a
potential biomarker for assessing therapeutic strategies
aiming at reducing the inflammatory component of AD
and thereby influencing neurodegeneration.
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